An interview with GPEI experts
WHO grants prequalification to innovative polio vaccine, nOPV2, as nearly 1 billion doses are administered
An interview with co-leads of GPEI’s nOPV Working Group on nOPV2 field use to date
World Health Assembly challenged to take urgent action before window of opportunity closes to eradicate polio; tackle cVDPVs with same urgen...
Rapid action needed to effectively quash transmission
Ananda talks about development of the nOPV2 vaccine its pathway to rollout, and field performance
The recommendation further advances nOPV2 as a critical new tool in the fight against circulating vaccine-derived poliovirus type 2 (cVDPV2)
Learn how the type 2 novel oral polio vaccine (nOPV2) is being rolled out across Africa to help more sustainably address outbreaks of a non-...
Renewed donor support critical to ending polio after recent rise in cases and COVID-19 setbacks
To rapidly and sustainably stop outbreaks of circulating vaccine-derived poliovirus type 2 (cVDPV2), a modified vaccine, known as novel oral...
Nouvel outil à utiliser pour lutter contre le PVDVc2